

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PRE-FILLED CONTAINER

This invention concerns pre-filled containers, cartridges and syringes. It relates most particularly to a new form of syringe which can be pre-filled, fitted with a hypodermic needle and packaged as a ready to use product.

The applicant has previously proposed various designs for the manufacture of injection moulded plastic syringes. For example reference is made to the applicant's previous patent applications PCT/AU92/00007 and PCT/AU95/00723. In both of these prior cases the pre-filled syringe was sealed at the needle end by a closure in the form of a stem which was separable from the syringe. Whilst the applicant's previous proposals were significant improvements on pre-filled products which had been available prior to these developments, the use of a separable stem to seal the syringe gives rise to certain difficulties. First, a stem which protrudes from the end of the syringe is susceptible to accidental knocks - both in production and in use and this can lead to contamination or inadvertent opening of the unit. Secondly, in a system such as that described in PCT/AU/00723 it is necessary to remove the stem from the needle fitting before a hypodermic needle can be attached. This means that the needle must be fitted in a separate step immediately prior to use. This can be inconvenient and there exists the possibility of contamination during the needle attachment operation.

It is an object of the present invention to provide a pre-filled syringe which is sealed in a manner which addresses, at least to some extent, the difficulties inherent in the prior units hereinbefore described.

In accordance with the present invention there is provided a pre-filled plastic syringe which includes:

- (a) a barrel;
- (b) a moveable stopper which seals the barrel at one end;
- (c) a needle fitting which is integral with the barrel and which is located at the end of the syringe remote from the moveable stopper; and
- (d) a closure which seals the syringe at its needling fitting end;

PRE-FILLED CONTAINER

This invention concerns pre-filled containers, cartridges and syringes. It relates most particularly to a new form of syringe which can be pre-filled, fitted
5 with a hypodermic needle and packaged as a ready to use product.

The applicant has previously proposed various designs for the manufacture of injection moulded plastic syringes. For example reference is made to the applicant's previous patent applications PCT/AU92/00007 and PCT/AU95/00723. In both of these prior cases the pre-filled syringe was sealed
10 at the needle end by a closure in the form of a stem which was separable from the syringe. Whilst the applicant's previous proposals were significant improvements on pre-filled products which had been available prior to these developments, the use of a separable stem to seal the syringe gives rise to certain difficulties. First, a stem which protrudes from the end of the syringe is
15 susceptible to accidental knocks - both in production and in use and this can lead to contamination or inadvertent opening of the unit. Secondly, in a system such as that described in PCT/AU/00723 it is necessary to remove the stem from the needle fitting before a hypodermic needle can be attached. This means that the needle must be fitted in a separate step immediately prior to use. This can be
20 inconvenient and there exists the possibility of contamination during the needle attachment operation.

It is an object of the present invention to provide a pre-filled syringe which is sealed in a manner which addresses, at least to some extent, the difficulties inherent in the prior units hereinbefore described.

25 In accordance with the present invention there is provided a pre-filled plastic syringe which includes:

- (a) a barrel;
- (b) a moveable stopper which seals the barrel at one end;
- (c) a needle fitting which is integral with the barrel and which is located
30 at the end of the syringe remote from the moveable stopper; and
- (d) a closure which seals the syringe at its needling fitting end;

wherein an injectable liquid is housed within the barrel between the moveable stopper and the closure and wherein the closure is located within the needle fitting and/or the barrel of the syringe.

Preferably, the needle fitting includes a hollow truncated cone, the interior of which is in liquid communication with the interior of the barrel. Most preferably, the needle fitting is in the form of a truncated cone surrounded by a peripheral wall spaced from the cone. An example of such a fitting is the "luer lock" needle fitting. A luer lock fitting incorporates a screw thread on the internal surface of the peripheral wall so to facilitate screw threaded engagement of a hypodermic needle onto the needle fitting. Hypodermic needles used in conjunction with luer lock needle fittings are attached at one end to a support which is conical, hollow and dimensioned to fit over and onto the central cone of the luer lock fitting. The base of the needle support includes a flange which is shaped to engage with the screw thread on the internal surface of the peripheral wall so that twisting of the hypodermic needle relative to the needle fitting facilitates engagement.

It is most preferred that the syringe of this invention utilise a luer lock needle fitting and that the syringe be used in conjunction with a hypodermic needle attached to a conical support as described above.

The closure may be a separate component located within the barrel or needle fitting such as by a friction fit or other suitable means. In such case it is preferred that the closure be made of such material and be of such thickness that it may be punctured readily.

However, the closure is preferably a wall portion which is frangibly connected to the inner surface of the barrel or to the inner surface of the needle fitting and which extends across the opening in the barrel or needle fitting. Most preferably the closure is located wholly within the needle fitting of the syringe. In the embodiment of the invention where the needle fitting includes a hollow truncated cone in liquid communication with the interior of the barrel it is preferred that the closure be an integral wall portion which is connected to the inner surface of the cone and extends across its opening. In this embodiment of the invention the wall portion can be located at any position along the inner wall of the needle fitting. Preferably it is frangibly attached to the inner surface of the truncated

cone and located at least 2.0 mm and most preferably at least 4.0 mm from the open end of the truncated cone so to reduce the prospect of the wall portion being broken away from the inner wall and (thus breaking the seal created by the wall portion) inadvertently.

5 In order that the syringe may be opened readily when it is desired to express the injectable liquid it is desirable that the closure either be puncturable by the rear needle of a standard double sided hypodermic needle (in which case the closure is positioned close to the open end of the needle fitting) or alternatively that it be frangible so that it may be detached or in part broken away
10 from the inner surface of the truncated cone or the barrel by utilizing a suitable tool.

 In a particularly preferred embodiment of the invention the syringe includes a truncated conical needle fitting and the closure is a wall portion which extends across the internal passage of the cone and is frangibly attached to the inner
15 surface of the cone.

 In this embodiment it is desirable that the wall portion include a circumferential weakened section at or adjacent to its connection to the inner surface of the cone. The weakened section thus creates a "tear line" along which the closure may be detached (at least in part) from the inner surface of the cone.
20 Preferably the wall portion is between 0.8 mm to 1.5 mm in thickness except in the weakened section where it is preferably between 0.05 to 0.2 mm in thickness. Whilst it is possible to utilize a weakened section which extends all the way around the wall portion this is not preferred as the application of a force against the wall portion in such an embodiment might result in the complete separation of
25 the closure from the needle fitting. Whilst this would not adversely affect the operation of the syringe it is considered undesirable to have the closure floating freely in the injectable liquid. Thus, it is preferred that the weakened section extend circumferentially through about 330 - 350° so that when the closure is broken away from the inner surface of the cone along the weakened section the
30 closure will still remain attached to the inside of the needle fitting and will be able to hinge about that section at or adjacent to the inner surface of the cone which is not weakened.

The seal provided by the wall portion may be broken by applying a force against the wall portion. A tool which incorporates a push rod of smaller diameter from the internal diameter of the cone and which is of sufficient length to reach the wall portion may be utilized for this purpose. Preferably such a tool has a flat end face sized to contact most of the surface area of the closure. Once the closure is detached, a hypodermic needle may be attached to the needle fitting making the syringe ready for immediate use.

Alternatively, and most preferably where the closure is frangibly connected to the needle fitting, the pre-filled syringe of the invention also includes a hollow closure opening conduit, a hypodermic needle and a needle support having an internal cavity, said hypodermic needle being attached at one end to the needle support and said needle support being positioned over (but not fully engaged with) the needle fitting, wherein a first end of said closure opening conduit is positioned within said internal cavity and a second end of the closure opening conduit is positioned within said needle fitting, the closure opening conduit being in liquid communication with the hypodermic needle and being of such length that movement of the needle support towards the moveable stopper end of the syringe will cause the closure opening conduit to break the seal provided by the closure.

Desirably the length of the closure opening conduit is such that full engagement of the needle support on the needle fitting provides sufficient movement of the needle support (and hence the closure opening conduit) to break the seal provided by the closure.

Preferably the cavity in the needle support includes an end face in which there is a centrally disposed aperture. The hypodermic needle may be fitted and secured at one end within the aperture so that it extends away from the cavity. The closure opening conduit is preferably located within the cavity with the first end abutting the end face of the housing with the internal passage therein in alignment with the aperture in the end face of the needle support. The other end of the closure opening conduit is preferably adjacent to or abuts the surface of the closure. In this way, movement of the needle support towards the moveable stopper end of the syringe will cause the end face to press against the first end of

the closure opening conduit and in turn apply pressure to the closure. By moving the support fully onto the needle fitting the closure opening conduit will be moved sufficiently to break the frangible connection of the closure to the needle fitting and thus facilitate direct liquid communication from the barrel of the syringe to the hypodermic needle past the opened closure and through the closure opening conduit.

The closure opening conduit may be integral with and extend from the needle support but it is preferably a separate component.

Preferably the closure opening conduit includes a central conduit and fins or ribs which extend outwardly therefrom so to minimize the contact between the closure opening conduit and the inner surface of the needle fitting. This reduces friction between the surfaces. As an alternative other closure opening means may be utilised which does not incorporate a conduit but is simply shaped to allow liquid passage. For example the closure opening means might be a solid rod which is of smaller diameter than the smallest diameter of the passage in the needle fitting with guide ribs which are configured to contact the inner surface of the needle fitting.

Desirably the pre-filled syringe also includes an overcap placed over the hypodermic needle. A tamper evident band may be provided around the base of the overcap so that prior removal of the overcap can be recognised by absence of the band or by its fracture.

The embodiment of the invention utilizing a closure opening conduit provides significant advantages in ease of use and avoidance of contamination. In particular, it is possible to injection mould all of the components, assemble and fill the syringe in an aseptic environment. The filled and assembled syringe may also be hermetically sealed within a clear plastic wrap such as cellophane prior to delivering the product out of the clean environment.

The pre-filled product may be delivered to practitioners with the hypodermic needle in position over the needle fitting but not fully engaged. In use the hypodermic needle may be pushed or twisted onto the needle fitting whilst the product is still in the hermitically sealed package. The complete seating of the hypodermic needle onto the needle fitting causes the seal formed by the closure

to be broken so that when the package is opened removal of the hypodermic needle overcap (if present) provides an opened pre-filled syringe ready for use and not susceptible to contamination by the application of additional parts or products to the syringe after the package has been opened.

5 The pre-filled plastic syringe of the invention is preferably manufactured from a thermoplastics material such as polypropylene. Other suitable materials include translucent and transparent plastics such as PET, polyamides or TPX. Other suitable materials are well known to those skilled in the art.

10 Examples of the invention are now described by reference to particularly preferred embodiments of the invention in which pre-filled syringes are injection moulded, assembled and packaged in a sterile environment and available for immediate use. The embodiments are shown in the following drawings in which:-

Figure 1 is a schematic diagram illustrating a pre-filled syringe packaged within an outer wrapper;

15 Figure 2 is a schematic diagram illustrating the pre-filled syringe shown in Figure 1 with the wrapper removed and prior to the syringe being opened;

Figure 3 is an end view of the pre-filled syringe shown in Figure 2 viewed from the plunger end;

20 Figure 4 is an enlarged schematic view of the needle fitting and closure of the pre-filled syringe shown in Figure 2;

Figure 5 is an enlarged view of the central cone of the needle fitting shown in Figure 4 and the associated closure;

25 Figure 6 is a schematic diagram illustrating the needle fitting end of the pre-filled syringe shown in Figure 2 with the hypodermic needle and needle support positioned over the end of the needle fitting of the syringe but prior to full engagement;

30 Figure 7 is a schematic diagram illustrating the needle fitting and hypodermic needle assembly as shown in Figure 6, after the hypodermic needle and needle support have been positioned firmly onto the needle fitting of the syringe;

Figure 8 is a schematic diagram illustrating the needle fitting end of the pre-filled syringe and the passage through which the injectable liquid can flow once the closure has been opened;

Figure 9 is a schematic representation of the closure opening conduit;

5 Figure 10 is a cross sectional view of a removable band intended for use in holding an overcap in position over the hypodermic needle prior to use;

Figure 11 is a schematic diagram illustrating an alternative embodiment of the invention utilising a double sided hypodermic needle;

10 Figure 12 is a schematic representation of the needle fitting end of the pre-filled syringe illustrated in Figure 11;

Figure 13 is a schematic diagram of the end of the truncated cone in the needle fitting illustrated in Figure 12; and

Figure 14 is a schematic representation of the double sided hypodermic needle with support and overcap.

15 Figure 1 is a schematic representation which illustrates how a preferred embodiment of the invention might be presented for distribution to doctors and other medical practitioners. The pre-filled syringe 1 is preferably manufactured by injection moulding all of the components in an aseptic environment, assembling and filling the syringe in the aseptic environment and sealing it within an outer
20 wrapper 17.

The syringe 1 which is illustrated without the protective packaging in Figure 2, includes a barrel 1a and a plunger rod 2 affixed to a moveable stopper 3. Moveable stopper 3 seals the barrel at one end - the other end of the barrel being sealed by a closure 9 which is integral with a central truncated cone 13a of the
25 needle fitting 13 at the other end of the syringe. The barrel 1a is filled with an injectable liquid 10 and this liquid is housed within the barrel 1a between moveable stopper 3 and closure 9.

An hypodermic needle 5 is secured to needle support 7. Needle support 7 includes an internal cavity 7a (best seen in Figure 6) and is positioned over the
30 end of truncated cone 13a of the needle fitting 13. Hypodermic needle 5 is hollow and is in liquid communication with cavity 7a.

A hollow closure opening conduit in the nature of a separate tube 21 (again seen better in Figure 6) is positioned between needle support 7 and closure 9 and the use of this tube in conjunction with needle support 7 in detaching closure 9 is described below.

5 Hypodermic needle 5 is protected by an overcap 6 which is held in position by a circumferential band 4 which is shown in full detail in Figure 10.

The needle fitting 13 also includes an outer peripheral wall 15.

Figure 3 illustrates the syringe from the plunger rod end of the syringe, showing thumb press 12, finger support flanges 16 and gripping ribs 18. These
10 features are shown simply to exemplify a particular embodiment of the invention but it will be appreciated that any type of plunger rod or moveable stopper mechanism, as known in the art, would be adequate for the purposes of the present invention.

Figure 4 illustrates the needle fitting end of the pre-filled syringe shown in
15 Figure 2. The needle fitting includes a central truncated cone 13a and a peripheral outer wall 15. This is in the nature of a standard "luer lock" type needle fitting and is thus suitable for use in conjunction with a standard hypodermic and needle support of the type as shown in Figure 2. The peripheral wall 15 includes a spiral rib 20 which facilitates screw threaded engagement of needle support 7
20 onto the needle fitting 13. The needle fitting 13 has an opening 22 between peripheral wall 15 and central truncated cone 13a.

Different from a standard luer lock is the provision of a closure 9 in the form of an integral end wall portion located within the central truncated cone 13a.

The closure 9 whilst being integral with the inner surface of central
25 truncated cone 13a is frangibly connected thereto as is better shown in Figure 5. Adjacent to the inner surface of truncated cone 13a closure 9 includes a tear line 8 being a circumferential portion of reduced thickness such that application of a force against closure 9 towards the moveable stopper end of the pre-filled syringe will cause the closure to tear away from the inner surface of truncated cone 13a
30 along the tear line 8 of reduced thickness. In the embodiment shown the syringe is made from polypropylene and closure 9 is about 1.2 mm in thickness. The tear line is about 0.1 mm in thickness. Preferably tear line 8 does not extend around

the full circumference of closure 9 so that when a force is applied against the closure, at least some part of the closure will remain attached to the inner surface of truncated cone 13a so to leave the closure 9 attached to a portion of the inner surface of truncated cone 13a. The diameter of the inner passage of central truncated cone 13a is slightly larger on the barrel side of the closure 9 so to
5 accommodate the closure when it is detached and folded back by tube 21.

The operation of the syringe is shown in more detail in Figures 6, 7 and 8. In Figure 6, the needle fitting end of the syringe is shown with closure 9 sealing the syringe. This is how the product would be supplied to end users. Needle
10 support 7 is positioned over the central truncated cone 13a but the flange 7b of needle support 7 has not been engaged with the screw thread portion 20 of the peripheral wall 15. Tube 21 is located with a first end in abutment against the end of cavity 7a and with the other end in abutment against the face of closure 9. Tube 21 has a central passage 21a which is aligned so that it is in direct fluid
15 communication with the passage 5a in hypodermic needle 5. Tamper indicating band 4 holds overcap 6 in position.

Figure 7 shows the needle fitting end of the pre-filled syringe after part of closure 9 has been detached from the inner surface of central truncated cone 13a. Preferably, this is achieved by applying a force to overcap 6 or
20 circumferential band 4 in the direction of the moveable stopper end of the pre-filled syringe. This force will in turn move the needle support 7 further onto truncated cone 13a. To engage the screw thread 20 it is preferred that the force be used in conjunction with a twisting action so to screw the needle support 7 onto central cone 13a and towards the moveable stopper end of the syringe. This
25 movement of support 7 causes a force to be applied to tube 21 which in turn applies a force to closure 9 causing it to tear away from the inner surface of central truncated cone 13a along tear line 8. In the preferred embodiment shown in Figure 7 the tear line 8 does not extend about the full circumference of the closure and thus it hinges to one side as can be clearly seen in Figure 7.
30 Preferably tube 21 is chamfered at the end. This facilitates easy insertion of tube 21 into the truncated cone 13a when the product is being assembled but it also means that the tube 21 is less likely to completely detach the closure 9 from the

inner surface of truncated cone 13a. The opened closure 9 is held between the inner surface of truncated cone 13a and the outer surface of tube 21 once needle support 7 has been firmly engaged on needle fitting 13.

5 In Figure 8 the needle fitting end of pre-filled syringe 1 is shown ready for use. Tamper evident band 4 has been removed together with overcap 6 (contrast with Figure 7). The injectable liquid 10 can now be expressed out of syringe 1 in the direction of the arrow shown in Figure 8 by moving plunger rod 2 towards the needle fitting end of the syringe. The liquid 10 will move in the direction of the arrow in Figure 8 through the passage 21a and thereafter through the hollow
10 hypodermic needle 5.

Figure 9 is a schematic representation showing tube 21 and Figure 10 is an enlarged cross section of tamper evident band 4. This band includes an internal rib 14 and an end flange 14a adapted to clip around the flange 6a of overcap 6.

15 An alternative embodiment of the invention is shown in Figures 11 to 14. In this embodiment, similar features to those described with respect to the first embodiment of the invention are similarly numbered. The primary difference between the embodiment of the invention shown in Figures 11 to 14 to that shown in Figures 1 to 10, concerns the position of closure 9 and the use of a
20 double sided hypodermic needle.

Turning to Figure 11, there is shown a pre-filled syringe 1 which has a barrel 1a, a plunger rod 2 and a moveable stopper 3. Needle fitting 13 includes a central truncated cone 13a and a peripheral wall 15. The hypodermic needle 5 is fitted to a needle support 7. In contrast to the embodiment shown in Figures 1 to
25 10, the hypodermic needle 5 extends through the needle support 7 and has a sharpened end 5b located within cavity 7a. When the product is assembled and filled, the sharpened end 5b of the hypodermic needle 5 is located close to but not in contact with closure 9.

The needle fitting 13 and central truncated cone 13a are shown in greater
30 detail in Figures 12 and 13. In order to ensure proper puncture of closure 9 by the sharpened end 5b of hypodermic needle 5 when the needle support 7 is fitted fully onto needle fitting 13, it is important that closure 9 be located close to the

end of central cone 13a. Whilst it may be located at the very end of central cone 13a, it is preferred that it be located a short distance within the cone, e.g. 0.5 mm from the end of cone 13a.

5 It will be appreciated that in use, securement of needle support 7 fully onto needle fitting 13 will cause movement of the sharp end 5b of hypodermic needle 5 towards and through closure 9 thus breaking the seal formed by closure 9 so that the injectable liquid 10 may be expressed from the syringe in similar manner to that described with respect to the first embodiment.

10 Figure 14 is an enlarged representation of hypodermic needle 5, needle support 7 and overcap 6.

It will be evident from the foregoing that the preferred embodiments of the invention as illustrated and described above can be manufactured, assembled and sealed within a wrapper all in an aseptic or clean environment. This product may be transported and stored with minimal risk of contamination and the wrapper can protect the syringe from any contamination and be removed only when the syringe is ready for use. As the mechanism for opening the syringe is activated by engaging the needle support 7 onto the needle fitting 13 there is no need for the needle fitting nor the needle support to be exposed to the environment and possible contamination prior to use. The consequent advantages in ease of use will be plain to those skilled in the art.

20 Various modifications and/or additions may be made to the embodiment hereinbefore described without departing from either the spirit or ambit of the present invention as defined in the following claims.

CLAIMS:

1. A pre-filled plastic syringe which includes:
 - (a) a barrel;
 - 5 (b) a moveable stopper which seals the barrel at one end;
 - (c) a needle fitting which is integral with the barrel and which is located at the end of the syringe remote from the moveable stopper; and
 - (d) a closure which seals the syringe at its needling fitting end;wherein an injectable liquid is housed within the barrel between the moveable
10 stopper and the closure and wherein the closure is located within the needle fitting and/or the barrel of the syringe.
2. A pre-filled plastic syringe as claimed in claim 1 wherein the needle fitting includes a hollow truncated cone, the interior of which is in liquid communication with the interior of the barrel.
- 15 3. A pre-filled plastic syringe as claimed in either claim 1 or claim 2 wherein the needle fitting is in the form of a truncated cone surrounded by a peripheral wall spaced from the cone.
4. A pre-filled plastic syringe as claimed in any one of claims 1 to 3 wherein the closure is made of such material and is of such thickness that it may be
20 punctured readily.
5. A pre-filled plastic syringe as claimed in any one of claims 1 to 4 wherein the closure is a separate component which is located within the barrel or within the needle fitting.
6. A pre-filled plastic syringe as claimed in any one of claims 1 to 4 wherein
25 the closure is a wall portion which is frangibly connected to the inner surface of the barrel or to the inner surface of the needle fitting and which extends across the opening of the barrel or of the needle fitting.
7. A pre-filled plastic syringe as claimed in any one of the previous claims wherein the closure is located wholly within the needle fitting of the syringe.
- 30 8. A plastic pre-filled syringe as claimed in claim 7 wherein the needle fitting includes an open ended hollow truncated cone in liquid communication with the

interior of the barrel and the closure is an integral wall portion which is connected to the inner surface of the truncated cone and extends across its opening.

9. A plastic pre-filled syringe as claimed in claim 8 wherein the wall portion is located at any position along the length of the inner wall of the needle fitting.

5 10. A plastic pre-filled syringe as claimed in claim 8 in which the closure is a wall portion which is frangibly attached to the inner surface of the truncated cone and located at least 2.0 mm from its open end.

11. A plastic pre-filled syringe as claimed in claim 10 wherein the wall portion is frangibly attached to the inner surface of the truncated cone and located at least
10 4.0 mm from its open end.

12. A plastic pre-filled syringe as claimed in any one of the previous claims in which the needle fitting is a luer lock needle fitting.

13. A plastic pre-filled syringe as claimed in any one of the previous claims in which the closure is puncturable by the rear needle of a double sided hypodermic
15 needle.

14. A plastic pre-filled syringe as claimed in any one of the previous claims wherein the closure may be detached or in part broken away from the inner surface of the needle fitting or the barrel by utilising a suitable tool.

15. A plastic pre-filled syringe as claimed in any one of claims 8 to 14 wherein
20 the closure is a wall portion which extends across the internal passage of the truncated cone and is frangibly attached to the inner surface thereof.

16. A plastic pre-filled syringe as claimed in claim 15 wherein said wall portion includes a circumferential weakened section at or adjacent to its connection to the inner surface of the truncated cone.

25 17. A plastic pre-filled syringe as claimed in claim 16 wherein said wall portion is between 0.8 mm to 1.5 mm in thickness except in the weakened section where it is between 0.05 to 0.2 mm in thickness.

18. A plastic pre-filled syringe as claimed in claim 17 wherein said weakened section does not extend all the way around the wall portion.

30 19. A plastic pre-filled syringe as claimed in claim 18 wherein the weakened section extends circumferentially through between 330 to 350° such that when the closure is broken away from the inner surface of the needle fitting along the

weakened section the closure will remain attached to the inner surface of the needle fitting and will be able to hinge about that section at or adjacent to the inner surface of the needle fitting which is not weakened.

20. A plastic pre-filled syringe as claimed in any one of the previous claims
5 which further includes a hollow closure opening conduit, a hypodermic needle and a needle support having an internal cavity, said hypodermic needle being attached at one end to the needle support and said needle support being positioned over the needle fitting, wherein a first end of said closure opening conduit is positioned within said internal cavity of the needle support and a
10 second end of the closure opening conduit is positioned within said needle fitting, the closure opening conduit being in liquid communication with the hypodermic needle and being of such length that movement of the needle support towards the moveable stopper end of the syringe will cause the closure opening conduit to break the seal provided by the closure.

15 21. A plastic pre-filled syringe as claimed in claim 20 wherein the length of the closure opening conduit is such that full engagement of the needle support on the needle fitting provides sufficient movement of the closure opening conduit to break the seal provided by the closure.

22. A plastic pre-filled syringe as claimed in claim 21 wherein the cavity in the
20 needle support includes an end face in which there is a centrally disposed aperture.

23. A plastic pre-filled syringe as claimed in claim 22 wherein the hypodermic needle is fitted and secured at one end within the aperture in the needle support and extends away from the cavity.


25 24. A plastic pre-filled syringe as claimed in claim 23 wherein the closure opening conduit is located within the cavity with the first end abutting the end face of the cavity with the internal passage therein in alignment with the aperture in the end face of the needle support.


25. A plastic pre-filled syringe as claimed in claim 24 wherein one end of the
30 closure opening conduit is adjacent to or abuts the surface of the closure.




26. A plastic pre-filled syringe as claimed in any one of claims 20 to 25 wherein said closure opening conduit is integral with and extends from the needle support.


27. A plastic pre-filled syringe as claimed in claim 26 wherein said closure opening conduit is a separate component.
28. A plastic pre-filled syringe as claimed in any one of claims 20 to 27 wherein said closure opening conduit includes a central conduit and fins or ribs which
5 extend outwardly therefrom.
29. A plastic pre-filled syringe as claimed in any one of claims 20 to 28 which further includes an overcap located over the hypodermic needle.
30. A plastic pre-filled syringe as claimed in any one of the previous claims wherein the filled and assembled syringe is hermetically sealed within a clear
10 plastic wrapper.
31. A method of using a plastic pre-filled syringe as claimed in any one of claims 20 to 29 wherein said hypodermic needle is pushed or twisted onto the needle fitting whilst the product is in a hermetically sealed package.
32. A method as claimed in claim 31 wherein the movement of the hypodermic
15 needle onto the needle fitting causes the closure opening conduit to break the seal provided by the closure.
33. A pre-filled plastic syringe as claimed in any one of the previous claims manufactured from a thermoplastics material.
34. A plastic pre-filled syringe substantially as hereinbefore described with
20 reference to what is shown in any one of the drawings.


FIG 1















5/7



6/7








FIG 11



INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 99/00422

A. CLASSIFICATION OF SUBJECT MATTERInt Cl⁶: A61M 5/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 wpat & japio + keywords(syringe, closure, seal, membrane, pre fill, pre load, pre charge, ready fill, ready load, ready charge, pierce, penetrate, detach, rupture, break, frangible, weaken)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/14100 A1 (ASTRA PHARMACEUTICALS PTY LTD) 17 May 1996 figure 1	1,2,3,5,12,14,30,33
A	GB 2307643 A (EPSOM GLASS INDUSTRIES LTD) 4 June 1997 figure 1	
A	US 4445895 A (MARGULIES) 1 May 1984	

☐ Further documents are listed in the continuation of Box C

☒ See patent family annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier application or patent but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 "&" document member of the same patent family

Date of the actual completion of the international search
 21 July 1999

Date of mailing of the international search report

28 JUL 1999

Name and mailing address of the ISA/AU
 AUSTRALIAN PATENT OFFICE
 PO BOX 200
 WODEN ACT 2606
 AUSTRALIA
 Facsimile No.: (02) 6285 3929

Authorized officer

GEOFF SADLIER
 Telephone No.: (02) 6283 2114

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/AU 99/00422

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
WO	96/14100	AU	37664/95	BR	9509431	CA	2204388
CZ	9701266	EP	789597	FI	971882	HU	77147
IL	115831	NO	971918	NZ	294778	PL	319941
SK	543/97	ZA	9509307				
GB	2307643	AU	77047/96	EP	871506	WO	9720586
US	4445895						

END OF ANNEX

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 24 FEB 2000

WIPO PCT

Applicant's or agent's file reference IRN 584263	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International application No. PCT/AU 99/00422	International filing date (<i>day/month/year</i>) 31 May 1999	Priority Date (<i>day/month/year</i>) 03 June 1998
International Patent Classification (IPC) or national classification and IPC Int. Cl.⁷ A61M 5/28		
Applicant ASTRA PHARMACEUTICALS PTY LTD et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of **3** sheets, including this cover sheet.
- ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).
- These annexes consist of a total of sheet(s).

3. This report contains indications relating to the following items:

- | | | |
|------|-------------------------------------|---|
| I | <input checked="" type="checkbox"/> | Basis of the report |
| II | <input type="checkbox"/> | Priority |
| III | <input type="checkbox"/> | Non-establishment of opinion with regard to novelty, inventive step and industrial applicability |
| IV | <input type="checkbox"/> | Lack of unity of invention |
| V | <input checked="" type="checkbox"/> | Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
| VI | <input type="checkbox"/> | Certain documents cited |
| VII | <input type="checkbox"/> | Certain defects in the international application |
| VIII | <input type="checkbox"/> | Certain observations on the international application |

Date of submission of the demand 18 November 1999	Date of completion of the report 15 February 2000
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer SUE THOMAS Telephone No. (02) 6283 2454

I. Basis of the report1. With regard to the **elements** of the international application:*

- ☒ the international application as originally filed.
- ☐ the description, pages , as originally filed,
 pages , filed with the demand,
 pages , filed with the letter of .
- ☐ the claims, pages , as originally filed,
 pages , as amended (together with any statement) under Article 19,
 pages , filed with the demand,
 pages , filed with the letter of .
- ☐ the drawings, pages , as originally filed,
 pages , filed with the demand,
 pages , filed with the letter of .
- ☐ the sequence listing part of the description:
 pages , as originally filed
 pages , filed with the demand
 pages , filed with the letter of .

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, was on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims 1-35	YES
	Claims	NO
Inventive step (IS)	Claims 1-35	YES
	Claims	NO
Industrial applicability (IA)	Claims 1-35	YES
	Claims	NO

2. Citations and explanations (Rule 70.7)

The invention of the amended claims is a prefilled plastic syringe with a needle fitting integral with the barrel and closure at the needle fitting end, which is a wall portion located within the barrel and/or needle fitting, the injectable liquid being within the barrel between the closure and a movable stopper sealing the barrel at the end remote from the needle fitting.

No individual citation or obvious combination of citations discloses such a syringe with closure at the needle-fitting end being a wall portion located within the barrel and/or needle fitting.

The closest art of WO 96/14100 provides a closure at the needle-fitting end but it is not a wall portion located within the barrel and/or needle fitting.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU 99/00422

A. CLASSIFICATION OF SUBJECT MATTER																						
Int Cl ⁶ : A61M 5/28																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
B. FIELDS SEARCHED																						
Minimum documentation searched (classification system followed by classification symbols) IPC: A61M																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) wpat & japio + keywords(syringe, closure, seal, membrane, pre fill, pre load, pre charge, ready fill, ready load, ready charge, pierce, penetrate, detach, rupture, break, frangible, weaken)																						
C. DOCUMENTS CONSIDERED TO BE RELEVANT																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
X	WO 96/14100 A1 (ASTRA PHARMACEUTICALS PTY LTD) 17 May 1996 figure 1	1,2,3,5,12,14,30,33																				
A	GB 2307643 A (EPSOM GLASS INDUSTRIES LTD) 4 June 1997 figure 1																					
A	US 4445895 A (MARGULIES) 1 May 1984																					
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex																						
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier application or patent but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"I."</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"I."	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"I."	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 21 July 1999		Date of mailing of the international search report 28 JUL 1999																				
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929		Authorized officer GEOFF SADLIER Telephone No.: (02) 6283 2114																				

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/AU 99/00422

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
WO	96/14100	AU	37664/95	BR	9509431	CA	2204388
CZ	9701266	EP	789597	FI	971882	HU	77147
IL	115831	NO	971918	NZ	294778	PL	319941
SK	543/97	ZA	9509307				
GB	2307643	AU	77047/96	EP	871506	WO	9720586
US	4445895						

END OF ANNEX

5F00
09701807

15

CORRECTED VERSION
PATENT COOPERATION TREATY

PCT
INTERNATIONAL PRELIMINARY EXAMINATION

(PCT Article 36 and Rule 70)

REC'D 28 NOV 2000
REPORT

WIPO PCT

Applicant's or agent's file reference IRN 584263	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416).
International Application No. PCT/AU99/00422	International Filing Date (<i>day/month/year</i>) 31 May 1999	Priority Date (<i>day/month/year</i>) 3 June 1998
International Patent Classification (IPC) or national classification and IPC Int. Cl. ⁷ A61M 5/28		
Applicant ASTRA PHARMACEUTICALS PTY LTD et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 3 sheets, including this cover sheet.
☒ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 6 sheet(s).

3. This report contains indications relating to the following items:

**CORRECTED
VERSION**

- | | | |
|------|-------------------------------------|---|
| I | <input checked="" type="checkbox"/> | Basis of the report |
| II | <input type="checkbox"/> | Priority |
| III | <input type="checkbox"/> | Non-establishment of opinion with regard to novelty, inventive step and industrial applicability |
| IV | <input type="checkbox"/> | Lack of unity of invention |
| V | <input checked="" type="checkbox"/> | Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
| VI | <input type="checkbox"/> | Certain documents cited |
| VII | <input type="checkbox"/> | Certain defects in the international application |
| VIII | <input type="checkbox"/> | Certain observations on the international application |

Date of submission of the demand 18 November 1999	Date of completion of the report 15 February 2000
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer SUE THOMAS Telephone No. (02) 6283 2454

I. Basis of the report

1. With regard to the elements of the international application:*

- ☐ the international application as originally filed.
- ☒ the description, pages 3-11, as originally filed,
 pages , filed with the demand,
 pages 1-2, received on 2 February 2000 with the letter of 2 February 2000
- ☒ the claims, pages , as originally filed,
 pages , as amended (together with any statement) under Article 19,
 pages , filed with the demand,
 pages 12-15, received on 2 February 2000 with the letter of 2 February 2000
- ☒ the drawings, pages 1/7-7/7, as originally filed,
 pages , filed with the demand,
 pages , received on with the letter of
- ☐ the sequence listing part of the description:
 pages , as originally filed
 pages , filed with the demand
 pages , received on with the letter of

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, was on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/fig.

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims 1-35	YES
	Claims	NO
Inventive step (IS)	Claims 1-35	YES
	Claims	NO
Industrial applicability (IA)	Claims 1-35	YES
	Claims	NO

2. Citations and explanations (Rule 70.7)

The invention of the amended claims is a prefilled plastic syringe with a needle fitting integral with the barrel and a closure at the needle-fitting end, which is a wall portion located within the barrel and/or needle fitting, the injectable liquid being within the barrel between the closure and a movable stopper sealing the barrel at the end remote from the needle fitting.

No individual citation or obvious combination of citations discloses such a syringe with a closure at the needle-fitting end being a wall portion located within the barrel and/or needle fitting.

The closest art of WO 96/14100 provides a closure at the needle-fitting end but it is not a wall portion located within the barrel and/or needle fitting.

PRE-FILLED CONTAINER

This invention concerns pre-filled containers, cartridges and syringes. It relates most particularly to a new form of syringe which can be pre-filled, fitted
5 with a hypodermic needle and packaged as a ready to use product.

The applicant has previously proposed various designs for the manufacture of injection moulded plastic syringes. For example reference is made to the applicant's previous patent applications PCT/AU92/00007 and PCT/AU95/00723. In both of these prior cases the pre-filled syringe was sealed
10 at the needle end by a closure in the form of a stem which was separable from the syringe. Whilst the applicant's previous proposals were significant improvements on pre-filled products which had been available prior to these developments, the use of a separable stem to seal the syringe gives rise to certain difficulties. First, a stem which protrudes from the end of the syringe is
15 susceptible to accidental knocks – both in production and in use and this can lead to contamination or inadvertent opening of the unit. Secondly, in a system such as that described in PCT/AU95/00723 it is necessary to remove the stem from the needle fitting before a hypodermic needle can be attached. This means that the needle must be fitted in a separate step immediately prior to
20 use. This can be inconvenient and there exists the possibility of contamination during the needle attachment operation.

It is an object of the present invention to provide a pre-filled syringe which is sealed in a manner which addresses, at least to some extent, the difficulties inherent in the prior units hereinbefore described.

25 In accordance with the present invention there is provided a pre-filled plastics syringe which includes:

- (a) a barrel;
- (b) a moveable stopper which seals the barrel at one end;
- (c) a needle fitting which is integral with the barrel and which is
30 located at the end of the syringe remote from the moveable stopper; and
- (d) a closure which seals the syringe at its needling fitting end;

wherein an injectable liquid is housed within the barrel between the moveable stopper and the closure and wherein the closure is a wall portion located within the barrel and/or the needle fitting of the syringe.

Preferably, the needle fitting includes a hollow truncated cone, the interior of which is in liquid communication with the interior of the barrel. Most preferably, the needle fitting is in the form of a truncated cone surrounded by a peripheral wall spaced from the cone. An example of such a fitting is the "luer lock" needle fitting. A luer lock fitting incorporates a screw thread on the internal surface of the peripheral wall so the facilitate screw threaded engagement of a hypodermic needle onto the needle fitting. Hypodermic needles used in conjunction with luer lock needle fittings are attached at one end to a support which is conical, hollow and dimensioned to fit over and onto the central cone of the luer lock fitting. The base of the needle support includes a flange which is shaped to engage with the screw thread on the internal surface of the peripheral wall so that twisting of the hypodermic needle relative to the needle fitting facilitates engagement.

It is most preferred that the syringe of this invention utilise a luer lock needle fitting and that the syringe be used in conjunction with a hypodermic needle attached to a conical support as described above.

The closure may be a separate component located within the barrel or needle fitting such as by a friction fit or other suitable means. In such case it is preferred that the closure be made of such material and be of such thickness that it may be punctured readily.

However, the closure is preferably a wall portion which is frangibly connected to the inner surface of the barrel or to the inner surface of the needle fitting and which extends across the opening in the barrel or needle fitting. Most preferably the closure is located wholly within the needle fitting of the syringe. In the embodiment of the invention where the needle fitting includes a hollow truncated cone in liquid communication with the interior of the barrel it is preferred that the closure be an integral wall portion which is connected to the inner surface of the cone and extends across its opening. In this embodiment of the invention the wall portion can be located at any position along the inner wall of the needle fitting. Preferably it is frangibly attached to the inner surface of the truncated

CLAIMS:

1. A pre-filled plastic syringe which includes:
 - 5 (a) a barrel;
 - (b) a moveable stopper which seals the barrel at one end;
 - (c) a needle fitting which is integral with the barrel and which is located at the end of the syringe remote from the moveable stopper; and
 - 10 (d) a closure which seals the syringe at its needling fitting end;wherein an injectable liquid is housed within the barrel between the moveable stopper and the closure and wherein the closure is a wall portion located within the barrel and/or the needle fitting of the syringe.
2. A pre-filled plastic syringe as claimed in claim 1 wherein the wall portion
15 is frangibly connected to the inner surface of the barrel or to the inner surface of the needle fitting.
3. A pre-filled plastic syringe as claimed in claim 2 wherein the wall portion extends across and is located within the opening of the barrel or of the needle fitting.
- 20 4. A pre-filled plastic syringe as claimed in any one of claims 1 to 3 wherein the closure is located wholly within the needle fitting of the syringe.
5. A pre-filled plastic syringe as claimed in any one of claims 1 to 4 wherein the wall portion is made of such material and is of such thickness that it may be punctured readily.
- 25 6. A pre-filled plastic syringe as claimed in any one of claims 1 to 5 wherein the needle fitting includes a hollow truncated cone, the interior of which is in liquid communication with the interior of the barrel once the seal created by the closure is broken.
7. A pre-filled plastic syringe as claimed in any one of claims 1 to 6 wherein
30 the needle fitting is in the form of a truncated cone surrounded by a peripheral wall spaced from the cone.
8. A pre-filled plastic syringe as claimed in any one of claims 1 to 7 wherein the closure is a separate component which is located within the barrel or within the needle fitting.

9. A plastic pre-filled syringe as claimed in claim 1 wherein the needle fitting includes an open ended hollow truncated cone the interior of which is in liquid communication with the interior of the barrel once the seal created by the closure is broken and the closure is an integral wall portion which is connected to the inner surface of the truncated cone and extends across its opening.
10. A plastic pre-filled syringe as claimed in claim 9 wherein the wall portion is located at any position along the length of the inner wall of the truncated cone.
11. A plastic pre-filled syringe as claimed in claim 10 in which the closure is a wall portion which is frangibly attached to the inner surface of the truncated cone and located at least 2.0 mm from its open end.
12. A plastic pre-filled syringe as claimed in claim 10 wherein the wall portion is frangibly attached to the inner surface of the truncated cone and located at least 4.0 mm from its end.
13. A plastic pre-filled syringe as claimed in any one of the previous claims in which the needle fitting is a luer lock needle fitting.
14. A plastic pre-filled syringe as claimed in any one of the previous claims in which the closure is puncturable by the rear needle of a double sided hypodermic needle.
15. A plastic pre-filled syringe as claimed in any one of the previous claims wherein the closure may be detached or in part broken away from the inner surface of the needle fitting or the barrel by utilising a suitable tool.
16. A plastic pre-filled syringe as claimed in any one of claims 10 to 13 wherein the closure is a wall portion which extends across the internal passage of the truncated cone and is frangibly attached to the inner surface thereof.
17. A plastic pre-filled syringe as claimed in claim 16 wherein said wall portion includes a circumferential weakened section at or adjacent to its connection to the inner surface of the truncated cone.
18. A plastic pre-filled syringe as claimed in claim 17 wherein said wall portion is between 0.8 mm to 1.5 mm in thickness except in the weakened section where it is between 0.05 mm and 0.2 mm in thickness.
19. A plastic pre-filled syringe as claimed in claim 18 wherein said weakened section does not extend all the way around the wall portion.

20. A plastic pre-filled syringe as claimed in claim 19 wherein the weakened section extends circumferentially through between 330 to 350° such that when the closure is broken away from the inner surface of the needle fitting along the weakened section the closure will remain attached to the inner surface of the
5 needle fitting and will be able to hinge about that section at or adjacent to the inner surface of the needle fitting which is not weakened.

21. A plastic pre-filled syringe as claimed in any one of the previous claims which further includes a hollow closure opening conduit, a hypodermic needle and a needle support having an internal cavity, said hypodermic needle being
10 attached at one end to the needle support and said needle support being positioned over the needle fitting, wherein a first end of said closure opening conduit is positioned within said internal cavity of the needle support and a second end of the closure opening conduit is positioned within said needle fitting, the closure opening conduit being in liquid communication with the
15 hypodermic needle and being of such length that movement of the needle support towards the moveable stopper end of the syringe will cause the closure opening conduit to break the seal provided by the closure.

22. A plastic pre-filled syringe as claimed in claim 21 wherein the length of the closure opening conduit is such that full engagement of the needle support
20 on the needle fitting provides sufficient movement of the closure opening conduit to break the seal provided by the closure.

23. A plastic pre-filled syringe as claimed in claim 22 wherein the cavity in the needle support includes an end face in which there is a centrally disposed aperture.

24. A plastic pre-filled syringe as claimed in claim 23 wherein the hypodermic
25 needle is fitted and secured at one end within the aperture in the needle support and extends away from the cavity.

25. A plastic pre-filled syringe as claimed in claim 24 wherein the closure opening conduit is located within the cavity with the first end abutting the end
30 face of the cavity with the internal passage therein in alignment with the aperture in the end face of the needle support.

26. A plastic pre-filled syringe as claimed in claim 25 wherein one end of the closure opening conduit is adjacent to or abuts the surface of the closure.

AMENDED SHEET
PCT/AU

27. A plastic pre-filled syringe as claimed in any one of claims 21 to 26 wherein said closure opening conduit is integral with and extends from the needle support.
28. A plastic pre-filled syringe as claimed in any one of claims 21 to 26
5 wherein said closure opening conduit is a separate component.
29. A plastic pre-filled syringe as claimed in any one of claims 21 to 28 wherein said closure opening conduit includes a central conduit and fins or ribs which extend outwardly therefrom.
30. A plastic pre-filled syringe as claimed in any one of claims 21 to 29 which
10 further includes an overcap located over the hypodermic needle.
31. A plastic pre-filled syringe as claimed in any one of the previous claims wherein the filled and assembled syringe is hermetically sealed within a clear plastic wrapper.
32. A method of using a plastic pre-filled syringe as claimed in any one of
15 claims 21 to 30 wherein said hypodermic needle is pushed or twisted onto the needle fitting whilst the product is in a hermetically sealed package.
33. A method as claimed in claim 32 wherein the movement of the hypodermic needle onto the needle fitting causes the closure opening conduit to break the seal provided by the closure.
- 20 34. A pre-filled plastic syringe as claimed in any one of the previous claims manufactured from a thermoplastics material.
35. A plastic pre-filled syringe substantially as hereinbefore described with reference to what is shown in any one of the drawings.